KDR and neoplasm: Ramucirumab prevents VEGF ligands binding to VEGFR2, preventing receptor dimerization and autophosphorylation at key tyrosine residues (Y951, Y1054, Y1059, Y1175, Y1214), deactivating multiple downstream pathways that promote angiogenesis and tumor progression [39,44,45,46,47].